Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02760498 · ClinicalTrials.gov registry record · Phase 2
Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
A Phase 2 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 432
- Enrollment target
NCT02760498 is a Phase 2 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 432 participants.
The verdict
NCT02760498, a Phase 2 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 432 participants
- Enrollment target
Study Summary
The goals of this study are to evaluate the clinical benefit and safety of cemiplimab in participants with metastatic (nodal or distant) Cutaneous Squamous Cell Carcinoma (CSCC), or unresectable locally advanced CSCC.
Interventions
- DRUG cemiplimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 432 participants |
| Start Date | 2016-04-07 |
| Est. Completion | 2023-10-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02760498
The ClinicalTrials.gov registry entry for NCT02760498 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 432 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cemiplimab is the first listed.
NCT02760498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02760498 about?
NCT02760498 is a clinical study titled "Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma". The goals of this study are to evaluate the clinical benefit and safety of cemiplimab in participants with metastatic (nodal or distant) Cutaneous Squamous Cell Carcinoma (CSCC), or unresectable locally advanced CSCC.
What is the current status of trial NCT02760498?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 432 participants. The study started on 2016-04-07. Estimated completion is 2023-10-18.
What interventions are being tested in trial NCT02760498?
The interventions under investigation include: cemiplimab (DRUG).
Who is sponsoring clinical trial NCT02760498?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.